JUBLPHARMA
Jubilant Pharmova
Each stock's 10,000-path forecast, rendered as light.
Jubilant Pharmova (JUBLPHARMA) Stock Analysis & Case Study
Is JUBLPHARMA a good buy? The data-driven verdict.
Jubilant Pharmova (JUBLPHARMA) trades at ₹956,on the numbers it tread carefully, a Downstox Snapshot Score of 39/100.
On the numbers, Jubilant Pharmova (JUBLPHARMA) tread carefully, a Downstox Snapshot Score of 39/100, weighing premium at 34.9× earnings, ROE of 6.5%, a 58% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
JUBLPHARMA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is JUBLPHARMA overvalued? JUBLPHARMA P/E vs its sector
JUBLPHARMA's P/E of 34.9× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.52% dividend yield is below the peer median of 1.65%.
JUBLPHARMA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of JUBLPHARMA history (14%/yr drift, 38%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| JUBLPHARMA 2027 | ₹644 | ₹1,039 | ₹1,698 | +7% |
| JUBLPHARMA 2028 | ₹562 | ₹1,116 | ₹2,212 | +15% |
| JUBLPHARMA 2029 | ₹516 | ₹1,201 | ₹2,760 | +24% |
| JUBLPHARMA 2030 | ₹486 | ₹1,288 | ₹3,409 | +33% |
| JUBLPHARMA 2031 | ₹462 | ₹1,377 | ₹4,014 | +43% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability JUBLPHARMA goes up, or doubles?
The bull case for JUBLPHARMA
- Jubilant Pharmova is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,760.
The bear case & risks
- At 34.9× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.
- Return on equity is a soft 6.5%, capital efficiency trails higher-quality peers.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹516.
JUBLPHARMA volatility & expected range, how bumpy is the ride?
Over the last 2.0 years JUBLPHARMA compounded at 14%/year with annualized volatility of 38%. That volatility implies a 1-year 80% range of ₹644–₹1,698, the honest backbone behind any single price target.
JUBLPHARMA price forecast, the full 60-month probability fan
JUBLPHARMA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds JUBLPHARMA hits common targets within the simulated horizon?
Full multi-horizon detail on the JUBLPHARMA price target & forecast page.
JUBLPHARMA Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. JUBLPHARMA scores 4/9,mixed financial health.
JUBLPHARMA MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy JUBLPHARMA with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 31.1% | 3.2× |
| ZerodhaCHEAPEST | 31.1% | 3.2× |
| DhanCHEAPEST | 31.1% | 3.2× |
Compare every broker on the JUBLPHARMA MTF page.
JUBLPHARMA vs peers,sector comparison
About Jubilant Pharmova: sector, index & market-cap context
Jubilant Pharmova (JUBLPHARMA) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹15,247 Cr. See more Nifty 200 stocks.
How the JUBLPHARMA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Jubilant Pharmova's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
JUBLPHARMA analysis, FAQs
Is Jubilant Pharmova (JUBLPHARMA) a good buy?
On the numbers, Jubilant Pharmova (JUBLPHARMA) tread carefully, a Downstox Snapshot Score of 39/100, weighing premium at 34.9× earnings, ROE of 6.5%, a 58% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is JUBLPHARMA overvalued or undervalued?
JUBLPHARMA trades at 34.9× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the JUBLPHARMA share price target for 2031?
JUBLPHARMA's probability-weighted 2031 median target is ₹1,377, with an 80% range of ₹462–₹4,014 (10,000-path Monte-Carlo).
What is the probability JUBLPHARMA doubles in 5 years?
The modelled probability of JUBLPHARMA reaching ₹1,933 (2×) within 5 years is 35%.
What is the bull case for JUBLPHARMA?
Jubilant Pharmova is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in JUBLPHARMA?
At 34.9× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished. Return on equity is a soft 6.5%, capital efficiency trails higher-quality peers.